Alcensa 150

Alcensa 150 is a prescription medication used to treat a type of lung cancer called anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. It is a kinase inhibitor that works by targeting the ALK protein and blocking its activity, which can help to slow down the growth of cancer cells.

Composition:

• Alectinib 150mg

Mechanism of Action:

Alectinib works by:

1. Inhibiting the activity of the ALK protein, which is a key player in the growth and spread of cancer cells
2. Blocking the signaling pathways that promote cancer cell growth and survival
3. Reducing the production of proteins that contribute to cancer cell growth and survival

Indications:

Alcensa 150 is approved for the treatment of:

• ALK-positive non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib
• ALK-positive NSCLC in patients who have not received prior chemotherapy

Dosage:

The recommended dosage of Alcensa 150 is:

• 150mg administered orally once daily
• The recommended duration of treatment is until disease progression or unacceptable toxicity occurs

Side Effects:

Common side effects of Alcensa 150 include:

1. Fatigue
2. Constipation
3. Nausea and vomiting
4. Diarrhea
5. Abdominal pain
6. Headache
7. Dizziness
8. Increased liver enzymes
9. Increased risk of infections
10. Increased risk of bleeding

Recommendation:

Alcensa 150 is recommended for patients with ALK-positive NSCLC who have not responded to other treatments or who have progressed on or are intolerant to crizotinib.

Important Note:

• Patients taking Alcensa 150 should be closely monitored for signs of liver damage or liver failure.
• Patients taking Alcensa 150 should avoid taking medications that may interact with it, such as warfarin or phenytoin.
• Pregnant or breastfeeding women should not use Alcensa 150, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Alcensa 150 and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of liver disease or liver dysfunction should be closely monitored while taking Alcensa 150.
• Patients with a history of bleeding disorders should be closely monitored while taking Alcensa 150.

Contraindications:

• Patients who are allergic to alectinib or any other component of Alcensa 150 should not use it.
• Patients who are pregnant or breastfeeding should not use Alcensa 150.
• Patients with severe liver disease or liver failure should not use Alcensa 150.

Warnings:

• Alcensa 150 can cause severe liver damage or liver failure, especially in patients with a history of liver disease.
• Patients with a history of liver disease or liver dysfunction should be closely monitored while taking Alcensa 150.
• Patients should report any changes in their liver function or symptoms of liver damage to their healthcare provider immediately.